Last reviewed · How we verify
Mervastrept (desoxymycin)
Mervastrept (generic name: desoxymycin) is a desoxymycin drug. It is currently in unknown development.
Mervastrept works by inhibiting bacterial protein synthesis.
Mervastrept (desoxymycin) is a small molecule drug of the desoxymycin class, but specific details about its development, commercial status, and approved indications are not available. As a desoxymycin, it is likely to target bacterial infections, but the exact target is unknown. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also not disclosed. Mervastrept's commercial status, including patent status and generic availability, is unclear. Further research is needed to understand its clinical use and safety profile.
At a glance
| Generic name | desoxymycin |
|---|---|
| Drug class | desoxymycin |
| Therapeutic area | Infectious Disease |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like factories that make proteins to keep you healthy. Bacteria are like tiny factories that make proteins to harm you. Mervastrept stops these bacterial factories from making proteins by binding to a specific part of the factory, preventing them from producing the proteins they need to grow and multiply.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mervastrept CI brief — competitive landscape report
- Mervastrept updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Mervastrept
What is Mervastrept?
How does Mervastrept work?
What is the generic name of Mervastrept?
What drug class is Mervastrept in?
What development phase is Mervastrept in?
Related
- Drug class: All desoxymycin drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing